MiNK Therapeutics (INKT) Competitors $7.28 +0.05 (+0.62%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. TARA, BHST, THTX, PROC, CTNM, ANIX, MIST, CCCC, TNYA, and HLVXShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Protara Therapeutics (TARA), BioHarvest Sciences (BHST), Theratechnologies (THTX), Procaps Group (PROC), Contineum Therapeutics (CTNM), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Protara Therapeutics BioHarvest Sciences Theratechnologies Procaps Group Contineum Therapeutics Anixa Biosciences Milestone Pharmaceuticals C4 Therapeutics Tenaya Therapeutics HilleVax MiNK Therapeutics (NASDAQ:INKT) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Is INKT or TARA more profitable? MiNK Therapeutics' return on equity of 0.00% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% Protara Therapeutics N/A -36.37%-33.29% Do insiders and institutionals hold more shares of INKT or TARA? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, INKT or TARA? MiNK Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Which has better earnings & valuation, INKT or TARA? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-2.89Protara TherapeuticsN/AN/A-$44.60M-$1.72-1.64 Does the media favor INKT or TARA? In the previous week, Protara Therapeutics had 3 more articles in the media than MiNK Therapeutics. MarketBeat recorded 3 mentions for Protara Therapeutics and 0 mentions for MiNK Therapeutics. Protara Therapeutics' average media sentiment score of 0.11 beat MiNK Therapeutics' score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MiNK Therapeutics Neutral Protara Therapeutics Neutral Do analysts recommend INKT or TARA? MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 415.46%. Protara Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 626.95%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryProtara Therapeutics beats MiNK Therapeutics on 11 of the 14 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.03M$2.85B$5.44B$8.92BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-2.8920.4927.2520.05Price / SalesN/A282.72426.50117.27Price / CashN/A41.7026.2128.59Price / Book-1.477.407.925.57Net Income-$9.51M-$55.04M$3.17B$248.56M7 Day Performance-0.89%3.67%4.48%7.44%1 Month Performance0.21%0.33%2.80%8.43%1 Year Performance-20.92%4.79%35.04%21.72% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics3.2654 of 5 stars$7.28+0.6%$37.50+415.5%-25.3%$29.03MN/A-2.8930Gap UpTARAProtara Therapeutics1.7902 of 5 stars$3.03+5.2%$20.50+576.6%+40.4%$111.12MN/A-1.7630BHSTBioHarvest SciencesN/A$6.73+0.3%$13.67+103.1%N/A$110.21M$25.19M-13.46N/APositive NewsTHTXTheratechnologiesN/A$2.36+0.4%N/A+120.4%$108.05M$88.67M-29.50140Upcoming EarningsPROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCTNMContineum Therapeutics2.1669 of 5 stars$3.97-3.4%$22.50+466.8%-80.2%$106.33M$50M-2.0231ANIXAnixa Biosciences2.6432 of 5 stars$3.30+2.5%$9.00+172.7%+46.3%$103.72M$210K-8.685MISTMilestone Pharmaceuticals2.28 of 5 stars$1.94+4.3%$7.00+260.8%+45.4%$99.44M$1M-2.4930CCCCC4 Therapeutics1.4507 of 5 stars$1.43+2.1%$12.00+739.2%-67.0%$99.41M$35.58M-0.97150Positive NewsTNYATenaya Therapeutics3.5935 of 5 stars$0.61+0.3%$6.25+922.6%-79.1%$99.16MN/A-0.53110News CoveragePositive NewsHLVXHilleVax3.212 of 5 stars$1.99+1.0%$3.00+50.8%-85.4%$98.78MN/A-0.9320Positive News Related Companies and Tools Related Companies Protara Therapeutics Competitors BioHarvest Sciences Competitors Theratechnologies Competitors Procaps Group Competitors Contineum Therapeutics Competitors Anixa Biosciences Competitors Milestone Pharmaceuticals Competitors C4 Therapeutics Competitors Tenaya Therapeutics Competitors HilleVax Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
